Followers | 14 |
Posts | 1,650 |
Boards Moderated | 0 |
Alias Born | 11/01/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wonder if they will change the symbol
Here we go!
I have a comment
That works for me
is that already priced in?
I don't know why we have to keep throwing around these time estimates
Right but how much do you think? 2,000? 10,000? 50,000? 100,000?
I don't know if there are any facts we can base this on but how much would you guess
Any guess at how many containers Aurora actually ordered?
I think a few after hour trades went through
I might able to finally get out the red here
Something is happening?
I'm not in love with it either but I don't think it is extremely important. Maybe they could move to a more simple style.
Just replying to the report that it was down.
It's working for me http://centaurustechnologiesinc.com/gem/
I took a profit off of it *Shrugs*
You might be wrong
It's happening?
SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) and Raises Target Price to $0.75
August 21, 2018
NEW YORK, NY / ACCESSWIRE / August 21, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Innovus Pharmaceuticals, Inc. (OTCQB: INNV) and has raised its target price to $0.75.
The report is available here: August 2018 Update Note.
Innovus Pharmaceuticals, Inc. (OTCQB: INNV, "Innovus") is a fast-growing commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health, respiratory disease and vitality. Led by CEO Dr. Bassam Damaj, Innovus is based in San Diego, CA and has demonstrated robust growth in its product offerings and annual revenues since we initiated coverage on the company in September 2014. Innovus revenues have grown from approximately $1.0mn in 2014 to $8.8mn in 2017 and guidance for more than $20mn in revenues in 2018.
Innovus reported another quarter of record in 2Q18 on August 14, 2018. In 2Q18, the company continued to generate strong top-line growth from solid execution in its proprietary Beyond Human™ sales and marketing platform, marking the fourth consecutive quarter of record revenue growth. Highlights include:
Record quarterly revenues in 2Q18. INNV 2Q18 revenues increased by 258.7% YoY to reach $7.3mn, versus $2.0mn in 2Q17.
Revenues rise 60.9% sequentially. Sequentially, revenues grew by an impressive 60.9% from $4.5mn in 1Q18, due to the impact of new products, execution in sales and marketing efforts on the company's Beyond Human platform, and international expansion.
1H18 topline well ahead of full-year 2017. Impressively, INNV generated $11.9mn in revenues during the first half of 2018 - more than $3mn above full-year 2017 revenues of $8.8mn.
Innovus raises guidance. Innovus CEO Bassam Damaj announced that the company was increasing its full-year outlook to $23mn - a significant increase from the company's guidance of "greater than $18mn" at the end of the last quarter.
INNV now markets 32 products in the US and 12 products in multiple countries through international commercial distribution partners. The company has experienced success in the Canadian market, which represented 14% of total revenues in the quarter.
Gross margins in 2Q18 remained healthy, coming in at 81%, consistent with 1Q18 and above 2017 levels of 79%.
Net loss was flat at in 2Q18 at ($1.8mn), or ($0.01) per share, matching 1Q18.
INNV ended the quarter with $1.6mn in cash on the balance sheet and financial debt of $2.0mn. The company had 207.2mn shares outstanding as of August 9, 2018.
Increasing target to $0.75 for Innovus
We are increasing our 2018E revenue estimate to $23mn following guidance from management. Our price target moves to $0.75 per share. We view INNV as a high growth company with several catalysts ahead as the company increases the number of products in its pipeline and expands its sales channels and geographic presence.
Please review important disclosures in the report and on our website at www.seethruequity.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC. www.Innovuspharma.com
About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high-quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative approach to deliver equity research of microcap and smallcap companies. SeeThruEquity has also been the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion since 2012.
SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.
Contact:
SeeThruEquity
info@seethruequity.com
SOURCE: SeeThruEquity
News powered by iR Direct — Copyright © 2018 Issuer Direct Corporation.
All Rights Reserved.
No we do not have more than rumor. These private convos can't be verified. It's literally word of mouth. Even if it's from Chas, it's still just words. I think the hype just leads to people dumping shares but I guess that works for some people
Silence would be better than the "any minute now" and "I heard a rumour" posts. We might as well bring LT back
Last update I can find is .70 but I'm starting to doubt that number since we pay for the research. Would be nice though
We've seen some movement in the right direction. I'll continue to hold
$CEOS looks like a new company
Looking forward to news here
No way I'm putting more money here, I'll just wait and see
I've been holding this since .03 smh
Lots of shares traded today
I just posted a businesswire link, it's out there. I don't know why ihub and brokers don't always show news
Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic
https://www.businesswire.com/news/home/20180719005039/en/
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that it has entered into a pilot program with the nationwide pharmaceutical chain CVS Pharmacy, Inc. (“CVS”), which is a subsidiary of CVS Health Corp (NYSE: CVS), to sell the Company’s product Androferti®, to increase sperm quality. If successful, the CVS pilot program could lead to the national pharmacy stocking and selling Androferti® on a scalable level nationwide and could expand to add additional Innovus Pharma products.
“We are very pleased to have been chosen by CVS to be part of their newly established in-store men’s health clinic,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “In addition, we are in discussion to potentially add more product under this program.”
About Androferti
Androferti®, is a patented dietary supplement shown in multiple published clinical trials to statistically increase seminal quality (concentration, motility, morphology and vitality) and enhance spermatozoa quality (decreases of vacuoles in the sperm nucleus, decreases DNA fragmentation, decreases the dynamics of sperm DNA fragmentation, and improvement on the inventory of mobile sperm (“REM”)).
The Company believes that Androferti® is the only product clinically proven in multiple published clinical trials to increase the Sperm Quality and enhance Spermatozoa Quality as compared to other products where the claims are based primarily on an ingredient used in the products.
According to reports by IBIS World in August 2014, the fertility market is estimated to be around $2 billion with a 2.5% annual increase. There are currently 682 In-Vitro Fertility (IVF) clinics in the U.S. Androferti® is currently available directly to IVF clinics and online at www.myandroferti.com at a price of $95 per box, which is sufficient for a one month supply. For optimal results from the published clinical trials optimal results of Androferti® are observed with 3 months of continuous use.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the Androferti® product and other products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.
Contacts
Randy Berholtz
Innovus Pharma Investor Relations
Tel: +1 858 249 7865
ir@innovuspharma.com
What is the CVS news?
you may be right
I've been here since 2012 so I'm familiar but that doesn't change the company's performance
I bought NSEH at .0003 5/2017 go figure
I'm in the red now
I doubt a meeting will give us anything more than talk
I was definitely green at the time of my post, I don't have a reason to lie. I definitely lost shares due to r/s
I down less than 1% now
Yep but why throw about $500 in the trash? Does someone know something we don't know?
Don't know what's going on but someone disagrees
Never mind I see now NSEH and a r/s which explains why I own hardly any shares but I i'm actually green so I guess that works for now
I can't remember when I bought this stock. Did a name change happen within the last year or two?
I wonder how well FlutiCare is selling now